BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors. 2022

Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.

Xanthine oxidase (XO) has been an important target for the treatment of hyperuricemia and gout. The analysis of potential interactions of pyrimidinone and 3-cyano indole pharmacophores present in the corresponding reported XO inhibitors with parts of the XO active pocket indicated that they both can be used as effective fragments for the fragment-based design of nonpurine XO inhibitors. In this paper, we adopted the fragment-based drug design strategy to link the two fragments with an amide bond to design the type 1 compounds 13a-13w,14c, 14d, 14f, 14g, 14j, 14k, and 15g. Compound 13g displayed an evident XO inhibitory potency (IC50 = 0.16 μM), which was 52.3-fold higher than that of allopurinol (IC50 = 8.37 μM). For comparison, type 2 compounds 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles (25c-25g) were also designed by linking the two fragments with a single bond directly. The results showed that compound 25c from the latter series displayed the best inhibitory potency (IC50 = 0.085 μM), and it was 98.5-fold stronger than that of allopurinol (IC50 = 8.37 μM). These results suggested that amide and single bonds were applicable for linking the two fragments together to obtain potent nonpurine XO inhibitors. The structure-activity relationship results revealed that hydrophobic groups at N-atom of the indole moiety were indispensable for the improvement of the inhibitory potency in vitro against XO. In addition, enzyme kinetics studies suggested that compounds 13g and 25c, as the most promising XO inhibitors for the two types of target compounds, acted as mixed-type inhibitors for XO. Moreover, molecular modeling studies suggested that the pyrimidinone and indole moieties of the target compounds could interact well with key amino acid residues in the active pocket of XO. Furthermore, in vivo hypouricemic effect demonstrated that compounds 13g and 25c could effectively reduce serum uric acid levels at an oral dose of 10 mg/kg. Therefore, compounds 13g and 25c could be potential and efficacious agents for the treatment of hyperuricemia and gout.

UI MeSH Term Description Entries
D008297 Male Males
D008892 Milk The off-white liquid secreted by the mammary glands of humans and other mammals. It contains proteins, sugar, lipids, vitamins, and minerals. Cow Milk,Cow's Milk,Milk, Cow,Milk, Cow's
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014969 Xanthine Oxidase An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria. Hypoxanthine Oxidase,Hypoxanthine Dehydrogenase,Hypoxanthine-Xanthine Oxidase,Purine-Xanthine Oxidase,Dehydrogenase, Hypoxanthine,Hypoxanthine Xanthine Oxidase,Oxidase, Hypoxanthine,Oxidase, Hypoxanthine-Xanthine,Oxidase, Purine-Xanthine,Oxidase, Xanthine,Purine Xanthine Oxidase
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.
November 2019, European journal of medicinal chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
March 2020, European journal of medicinal chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.
May 2024, European journal of medicinal chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
N-(3-cyano-1H-indol-5-yl)isonicotinamide and N-(3-cyano-1H-indol-5-yl)-1H-benzo[d]imidazole-5-carboxamide derivatives: Novel amide-based xanthine oxidase inhibitors.
October 2021, Bioorganic chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.
March 2015, Bioorganic & medicinal chemistry letters,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
March 2006, The Journal of pharmacy and pharmacology,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design, synthesis and biological evaluation of N-(3-(1H-tetrazol-1-yl)phenyl)isonicotinamide derivatives as novel xanthine oxidase inhibitors.
December 2019, European journal of medicinal chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Amide-based xanthine oxidase inhibitors bearing an N-(1-alkyl-3-cyano-1H-indol-5-yl) moiety: Design, synthesis and structure-activity relationship investigation.
December 2021, Bioorganic chemistry,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Design, synthesis, and biological evaluation of 5-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)benzonitrile derivatives as xanthine oxidase inhibitors.
February 2018, Chemical biology & drug design,
Bing Zhang, and Yulin Duan, and Yuwei Yang, and Qing Mao, and Fengwei Lin, and Jun Gao, and Xiwen Dai, and Peng Zhang, and Qiuhua Li, and Jinxin Li, and Ronghua Dai, and Shaojie Wang
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.
February 2016, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!